Canaccord Genuity Group Lowers Prestige Consumer Healthcare (NYSE:PBH) Price Target to $88.00

Prestige Consumer Healthcare (NYSE:PBH) had its price target reduced by analysts at Canaccord Genuity Group from $100.00 to $88.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price target points to a potential upside of 47.03% from the company’s previous close.

Other analysts have also issued research reports about the stock. Jefferies Financial Group cut their target price on shares of Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research report on Monday, October 27th. Wall Street Zen downgraded Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Oppenheimer reduced their price objective on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Finally, Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Wednesday, September 24th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $85.33.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $59.85 on Friday. Prestige Consumer Healthcare has a twelve month low of $59.51 and a twelve month high of $90.04. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The stock’s 50-day simple moving average is $62.98 and its 200 day simple moving average is $73.18. The firm has a market capitalization of $2.95 billion, a PE ratio of 14.05, a price-to-earnings-growth ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last issued its earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, topping the consensus estimate of $0.97 by $0.10. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $274.11 million during the quarter, compared to the consensus estimate of $257.14 million. During the same quarter in the previous year, the firm earned $1.09 earnings per share. The business’s quarterly revenue was down 3.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UMB Bank n.a. raised its position in shares of Prestige Consumer Healthcare by 81.8% during the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after acquiring an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its position in Prestige Consumer Healthcare by 312.5% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new position in Prestige Consumer Healthcare during the 2nd quarter worth approximately $27,000. First Horizon Corp bought a new position in Prestige Consumer Healthcare during the 3rd quarter worth approximately $32,000. Finally, Hantz Financial Services Inc. lifted its position in shares of Prestige Consumer Healthcare by 373.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock worth $43,000 after purchasing an additional 538 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.